Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognosis in juvenile arthritis.

B M Ansell

    Advances in Experimental Medicine and Biology
    |December 22, 1999
    PubMed
    Summary

    Juvenile arthritis, a condition affecting children under 16, requires careful diagnosis and prognosis. Early recognition and treatment are key, though outcomes vary based on disease type and severity.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Still's Disease Followed into Adult Life.

    Proceedings of the Royal Society of Medicine·2010
    Same author

    Sarcoidosis in the pediatric age.

    Clinical and experimental rheumatology·2002
    Same author

    Rheumatic disease mimics in childhood.

    Current opinion in rheumatology·2000
    Same author

    Bone mineral content and bone mineral metabolism: changes after growth hormone treatment in juvenile chronic arthritis.

    The Journal of rheumatology·2000
    Same author

    Cutaneous vasculitis in children.

    Clinics in dermatology·1999
    Same author

    Chlorambucil therapy in juvenile chronic arthritis (juvenile idiopathic arthritis)

    The Journal of rheumatology·1999

    Area of Science:

    • Pediatric Rheumatology
    • Immunology
    • Clinical Medicine

    Background:

    • Juvenile arthritis (JA) is defined as arthritis in individuals under 16 years old, persisting for at least six weeks.
    • Accurate prognosis of JA depends on early recognition and appropriate care, but treatment response can be variable.
    • Historically, JA subclassification evolved through meetings like Park City and EULAR, defining subgroups such as systemic, polyarthritis, and pauci-articular onset.

    Purpose of the Study:

    • To review the historical context and evolution of juvenile arthritis classification and prognosis.
    • To highlight the importance of early diagnosis and the impact of disease subtypes on patient outcomes.
    • To discuss the advancements in therapeutic approaches for juvenile arthritis, particularly since the 1990s.

    Main Methods:

    • Review of historical literature and key international meetings (e.g., Park City, EULAR, ILAR) concerning juvenile arthritis.
    • Analysis of factors influencing disease prognosis, including joint involvement, disease activity, and patient demographics (e.g., gender).
    • Examination of the evolution of diagnostic criteria and therapeutic interventions for juvenile arthritis over time.

    Main Results:

    • Prognosis in JA varies, with fewer affected joints generally leading to better outcomes compared to systemic disease or seropositive juvenile rheumatoid arthritis.
    • Complications of JA can include joint deformities, osteoporosis, amyloidosis, growth disturbances, chronic iridocyclitis, and psychosocial issues.
    • The introduction of more aggressive therapies like methotrexate and sulphasalazine in the 1990s marked a significant shift in treatment strategies.

    Conclusions:

    • Accurate subclassification and early recognition are crucial for predicting juvenile arthritis outcomes.
    • Treatment response in JA is variable, underscoring the need for personalized therapeutic approaches.
    • Ongoing research and international collaboration are essential for refining diagnostic criteria and improving management of juvenile arthritis.

    Related Experiment Videos